Abstract
BACKGROUND: Myocardial infarction (MI) has been linked to changes in the blood microbiome, yet the interplay between microbiome and metabolome remains poorly understood. This study integrates blood microbiome profiling and metabolomic analysis to uncover biomarkers and pathways associated with MI. METHODS: Using 16 S rRNA sequencing and LC-MS metabolomics, blood samples from 24 MI patients and 24 healthy controls were analyzed. Microbial diversity, key taxa, metabolites, and their functional implications were evaluated. RESULTS: While alpha and beta diversity of the microbiome showed no significant differences, three bacterial taxa (Proteobacteria, Gammaproteobacteria, and Bacilli) and twenty metabolites (e.g., UPD-L-Ara4O, Urotensin-related peptide, and 9-hydroxy octadecanoic acid) were identified as potential biomarkers, achieving an AUC of 0.99-1. Functional pathway analysis revealed upregulation in glycerolipid metabolism and mTOR signaling pathways, which were significantly correlated with clinical markers of MI. CONCLUSION: This integrative approach highlights the diagnostic potential of blood microbiome-metabolome dynamics in MI and suggests mechanistic pathways that could guide future interventions.